Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective randomized phase 3 trial of TheraSphere vs sorafenib in unresectable hepatocellular carcinoma with portal vein thrombosis
2012-005375-14Phase 3Completed
- Sponsor
- Biocompatibles
- Start
- Apr 2013
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
A Phase 3 trial of yttrium-90, sorafenib in hepatocellular carcinoma (HCC), portal vein thrombosis (PVT), sponsored by Biocompatibles. Started Apr 2013; status: completed.
02
Drugs
yttrium-90sorafenib
03
Conditions
hepatocellular carcinoma (HCC)portal vein thrombosis (PVT)
Beyond the preview
Go deeper on 2012-005375-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005375-14.